VIVEbiotech and VIRALGEN, specialized in the production of viral vectors for gene therapy, have organized the I Symposium on Gene Therapy Manufacturing, a meeting that will take place in San Sebastián on October 21.

VIVEbiotech has participated in two international conferences specialized in gene therapy in the months of September and October of this year.

VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its strategic plan, which highlights the construction of three new cleanrooms and the incorporation of new equipment that will multiply its production capacity substantially.

The Minister of Health, María Luisa Carcedo, has visited VIVEbiotech.

VIVEbiotech has joined the #juntosporeldravet campaign organized by the Apoyodravet association this week, coinciding with the International Dravet Syndrome Awareness Day.

VIVEbiotech, a company specialized in the production of lentiviral vectors for their use in gene therapy, has received notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office.